Pemvidutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A dual GLP-1/glucagon receptor agonist (1:1 ratio) for weight loss and fatty liver disease (MASH/MASLD). The human evidence is unusually solid: trials show substantial liver fat reduction and meaningful weight loss, with tolerability varying by trial and dose. Antifibrotic benefit and long-term durability are still preliminary, based on limited Phase 2 data. GI side effects are the main risk, and it is not yet FDA-approved.
Read Full recordStudied uses & evidence
Studied uses(6)
Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.
LowBiopsy fibrosis endpoint was negative, leaving only surrogate marker evidence, still preliminary.
Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)
HighConfirmed in a randomized 24-week trial, with up to 75% relative liver fat reduction vs placebo.
Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)
HighHuman RCT data show significant body weight reduction, up to 6.2% at 24 weeks vs placebo.
Evidence limits
- Evidence Level
- Moderate-Strong Evidence
Pemvidutide has Phase 2b data in MASH (n=212, 48 weeks) and Phase 2 data in MASLD (n=64, 24 weeks), both demonstrating significant efficacy on liver endpoints and weight loss. FDA End-of-Phase 2 meeting completed with alignment on Phase 3 design. The PERFORMA Phase 3 registrational trial is underway.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 class effect on pancreatitis risk.
Severe gastroparesis
HighGLP-1 component slows gastric emptying.
General cautions
Pregnancy
AbsoluteInvestigational — no reproductive safety data.
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events (GLP-1 class effect)
HighGlucagon-mediated effects on blood glucose
LowLimited Phase 3 data
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.